Results 11 to 20 of about 1,819,904 (233)
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
core +9 more sources
Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
Clinical Medicine Insights: Cardiology, 2013 Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing.
Matthew G. Whitbeck, Robert J. Applegate
doaj +2 more sources
Everolimus-eluting stents: update on current clinical studies
Medical Devices: Evidence and Research, 2011 Dominic J Allocco, Anita A Joshi, Keith D DawkinsBoston Scientific Corporation, Natick, MA, USAAbstract: Everolimus-eluting stents (EES) have become the most commonly implanted coronary stents worldwide.
Allocco DJ, Joshi AA, Dawkins KD
doaj +1 more source
Everolimus-eluting coronary stents
Medical Devices: Evidence and Research, 2010 Alejandro Saez, Raul MorenoDivision of Interventional Cardiology, University Hospital La Paz, Madrid, SpainAbstract: Bare metal stents enabled a reduction in the risk of early procedural complications and restenosis in comparison with balloon angioplasty
Alejandro Saez, Raul Moreno
doaj +1 more source
Drug-eluting coronary stents – focus on improved patient outcomes
Patient Related Outcome Measures, 2011 Zehra Jaffery, Amit Prasad, John H Lee, Christopher J WhiteDepartment of Cardiovascular Diseases, The John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA, USAAbstract: The development of stent has been a major advance in
Jaffery Z, Prasad A, Lee JH, White CJ
doaj +1 more source
Comparative outcomes of drug-eluting stents and drug-eluting balloons in treating in-stent restenosis. [PDF]
Arch Med Sci Atheroscler DisIntroduction Several treatment modalities have been proposed and used for bare-metal in-stent restenosis (ISR). We compared the efficacy of drug-eluting balloons (DEB) versus drug-eluting stents (DES) in the treatment of ISR in terms of binary restenosis,
Mahajan N, Singal G, Sharma M.
europepmc +2 more sources
Promoting vascular healing using nanofibrous ticagrelor-eluting stents
International Journal of Nanomedicine, 2018 Cheng-Hung Lee,1 Ming-Jer Hsieh,1 Kuo-Sheng Liu,2,3 Che-Wei Cheng,3 Shang-Hung Chang,1 Shih-Jung Liu,3,4 Chao-Jan Wang,5 Ming-Yi Hsu,5 Kuo-Chun Hung,1 Yung-Hsin Yeh,1 Wei-Jan Chen,1 I-Chang Hsieh,1 Jyuhn-Huarng Juang,6 Ming-Shien Wen1 1Division of ...
Lee CH +13 more
doaj +1 more source
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
E Liana, Falcone, Navdeep, Tangri
openaire +4 more sources
A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model
Frontiers in Pharmacology, 2023 Introduction: Most drug-eluting stents (DESs) inhibit intimal hyperplasia but impair re-endothelialization. This study aimed to evaluate in vivo strut coverage and neointimal growth in a new glycyrrhizin acid (GA)-eluting stent.Methods: New Zealand White
Shuai Teng +6 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: The second-generation drug-eluting stents have been used to treat chronic total occlusion lesion. However, there is limited evidence of the clinical outcomes that whether the second-generation drug-eluting stents is superior to
Xuan Qiao +5 more
doaj +1 more source